WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H461605
CAS#: 121454-18-0
Description: S 11566 is a selective dopamine D3 receptor antagonist.
Hodoodo Cat#: H461605
Name: S 11566
CAS#: 121454-18-0
Chemical Formula: C18H27NO
Exact Mass: 273.21
Molecular Weight: 273.420
Elemental Analysis: C, 79.07; H, 9.95; N, 5.12; O, 5.85
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: S 11566; S-11566; S11566;
IUPAC/Chemical Name: N,N-dipropyl-2,3,5,6,7,8-hexahydronaphtho[2,3-b]furan-7-amine
InChi Key: IJICKINLCUKIHY-UHFFFAOYSA-N
InChi Code: InChI=1S/C18H27NO/c1-3-8-19(9-4-2)17-6-5-14-11-15-7-10-20-18(15)13-16(14)12-17/h11,13,17H,3-10,12H2,1-2H3
SMILES Code: CCCN(CCC)C1CCC2=C(C=C3OCCC3=C2)C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 273.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Millan MJ, Gressier H, Brocco M. The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats. Eur J Pharmacol. 1997 Mar 5;321(3):R7-9. PubMed PMID: 9085054.
2: Millan MJ, Audinot V, Melon C, Newman-Tancredi A. Evidence that dopamine D3 receptors participate in clozapine-induced hypothermia. Eur J Pharmacol. 1995 Jul 4;280(2):225-9. PubMed PMID: 7589191.
3: Millan MJ, Peglion JL, Vian J, Rivet JM, Brocco M, Gobert A, Newman-Tancredi A, Dacquet C, Bervoets K, Girardon S, et al. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther. 1995 Nov;275(2):885-98. PubMed PMID: 7473180.
4: Rivet JM, Audinot V, Gobert A, Peglion JL, Millan MJ. Modulation of mesolimbic dopamine release by the selective dopamine D3 receptor antagonist, (+)-S 14297. Eur J Pharmacol. 1994 Nov 24;265(3):175-7. PubMed PMID: 7875234.
5: Gobert A, Rivet JM, Audinot V, Cistarelli L, Spedding M, Vian J, Peglion JL, Millan MJ. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther. 1995 Nov;275(2):899-913. PubMed PMID: 7473181.
6: Audinot V, Newman-Tancredi A, Gobert A, Rivet JM, Brocco M, Lejeune F, Gluck L, Desposte I, Bervoets K, Dekeyne A, Millan MJ. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. J Pharmacol Exp Ther. 1998 Oct;287(1):187-97. PubMed PMID: 9765337.
7: Millan MJ, Audinot V, Rivet JM, Gobert A, Vian J, Prost JF, Spedding M, Peglion JL. S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats. Eur J Pharmacol. 1994 Aug 1;260(2-3):R3-5. PubMed PMID: 7988633.
8: Newman-Tancredi A, Audinot V, Jacques V, Peglion JL, Millan MJ. [3H](+)S 14297: a novel, selective radioligand at cloned human dopamine D3 receptors. Neuropharmacology. 1995 Dec;34(12):1693-6. PubMed PMID: 8788967.
9: Yoshikawa T, Yoshida N. The possible involvement of dopamine D3 receptors in the regulation of gastric emptying in rats. Life Sci. 2010 Nov 20;87(19-22):638-42. doi: 10.1016/j.lfs.2010.09.027. Epub 2010 Oct 1. PubMed PMID: 20888837.
10: Gobert A, Lejeune F, Rivet JM, Cistarelli L, Millan MJ. Dopamine D3 (auto) receptors inhibit dopamine release in the frontal cortex of freely moving rats in vivo. J Neurochem. 1996 May;66(5):2209-12. PubMed PMID: 8780056.
11: Perachon S, Betancur C, Pilon C, Rostène W, Schwartz JC, Sokoloff P. Role of dopamine D3 receptors in thermoregulation: a reappraisal. Neuroreport. 2000 Jan 17;11(1):221-5. PubMed PMID: 10683862.
12: Lejeune F, Millan MJ. Activation of dopamine D3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurones in vivo. Eur J Pharmacol. 1995 Mar 14;275(3):R7-9. PubMed PMID: 7768288.
13: Morris BJ, Newman-Tancredi A, Audinot V, Simpson CS, Millan MJ. Activation of dopamine D(3) receptors induces c-fos expression in primary cultures of rat striatal neurons. J Neurosci Res. 2000 Mar 15;59(6):740-9. PubMed PMID: 10700011.
14: Millan MJ, Girardon S, Monneyron S, Dekeyne A. Discriminative stimulus properties of the dopamine D3 receptor agonists, PD128,907 and 7-OH-DPAT: a comparative characterization with novel ligands at D3 versus D2 receptors. Neuropharmacology. 2000 Feb 14;39(4):586-98. PubMed PMID: 10728880.
